In a deal without disclosing financial terms, China Resources Biopharma has licensed in U.S. firm Ab Studio's ABS-VIR-001, a trispecific antibody developed as a prophylaxis and therapeutic against SARS-CoV-2 infection. More news from 3D Medicines, SinoMab and Gloria.
Clover Biopharmaceuticals is conducting trials to evaluate its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a universal COVID-19 booster vaccine.